A pivotal study of INCB-123667 in ovarian cancer
Latest Information Update: 17 Sep 2024
Price :
$35 *
At a glance
- Drugs INCB 123667 (Primary)
- Indications Ovarian cancer
- Focus Registrational; Therapeutic Use
- 17 Sep 2024 New trial record
- 14 Sep 2024 According to an Incyte media release, the company will expected to begin this study in 2025.